Company Overview of Albireo AB
Albireo AB, a biotechnology company, focuses on the development of therapeutic drugs for gastrointestinal and liver diseases. Its pipeline programs include Elobixibat IBAT inhibitor for IBS-C and chronic constipation; A4250 IBAT inhibitor for cholestatic liver diseases; A3384 for bile acid mal-absorption; locally active PPAR agonists for IBD; IBAT inhibitor for type 2 diabetes and mellitus; and A3914 and A5425 NK antagonist for atopic dermatitis and psoriasis post-operative adhesions. Albireo AB was founded in 2008 and is based in Gothenburg, Sweden.
Arvid Wallgrens Backe 20
Gothenburg, 413 46
Founded in 2008
46 3 17 41 14 80
46 31 82 02 23
Key Executives for Albireo AB
Albireo AB Key Developments
Similar Private Companies By Industry
|Plant Science Sweden AB||Europe|
|Vanadis Diagnostics, AB||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
To contact Albireo AB, please visit www.albireopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.